Jul 5, 2017   SOURCE: PR NewsWire

Juniper Pharmaceuticals Announces Results of 2017 Annual Meeting

BOSTON, July 5, 2017 /PRNewswire/ -- Juniper Pharmaceuticals (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today announced the results of its Annual Meeting of Shareholders held in Boston on June 30, 2017.

Six of the seven members of the Juniper Board of Directors named in the 2017 proxy statement received a majority of the shareholder votes cast: Dr. Cristina Csimma, James A. Geraghty, Dr. Mary Ann Gray, Ann Merrifield, Dr. Nikin Patel and Alicia Secor.

Additional results from the Annual Meeting are as follows:

    --  Shareholders approved the ratification of the appointment of
        PricewaterhouseCoopers LLP as Juniper's independent registered public
        accounting firm.
    --  Shareholders approved a non-binding, advisory say-on-pay vote to approve
        the compensation of Juniper's named executive officers.
    --  Shareholders approved a non-binding, advisory vote on the frequency of
        future say-on-pay votes to take place every year.

At the Annual Meeting, 3,245,151 shares, or approximately 44% of all votes cast were voted in favor of the re-election of Dr. Frank Armstrong to the Board of Directors. As less than a majority of votes cast were voted in favor of Dr. Armstrong's re-election, Dr. Armstrong has delivered a notice of resignation to the Board of Directors in accordance with the Amended and Restated By-Laws of the Company.

In accordance with the Amended and Restated By-Laws, the Board of Directors, upon recommendation of the Nominating and Corporate Governance Committee, will determine whether to accept or reject Dr. Armstrong's resignation, and will publicly announce this decision within ninety days of the date of the certification of the election results. Dr. Armstrong will continue to serve as a director of the Company until a decision is made.

About Juniper Pharmaceuticals
Juniper Pharmaceuticals, Inc. is focused on developing therapeutics that address unmet medical needs in women's health. The Company is advancing a pipeline of proprietary product candidates that leverage its differentiated intravaginal ring technology and when appropriate the 505(b)(2) regulatory pathway. Targeted product development investments are enabled by Juniper's core operating business: the CRINONE(®) (progesterone gel) franchise and Juniper Pharma Services, which provides high-end fee-for-service pharmaceutical development and clinical trials manufacturing to clients. Please visit www.juniperpharma.com for more information.

Juniper Pharmaceuticals(TM) is a trademark of Juniper Pharmaceuticals, Inc., in the U.S. and EU.

CRINONE(®) is a registered trademark of Merck KGaA, Darmstadt, Germany, outside the U.S. and of Allergan plc in the U.S.

Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the Nominating and Corporate Governance Committee and Board consideration of whether to accept or reject Dr. Armstrong's resignation from the Board and statements concerning the Company's product development programs. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include, but are not limited to: risks associated with the drug development process generally, including the outcomes of planned clinical trials and the regulatory review process; the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies or following commercial launch, if such product candidates are approved; risks associated with obtaining, maintaining and protecting intellectual property; risks associated with Juniper Pharmaceuticals' ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; the risk of competition from currently approved therapies and from other companies developing products for similar uses; risk associated with Juniper Pharmaceuticals' ability to manage operating expenses and/or obtain additional funding to support its business activities; and risks associated with Juniper Pharmaceuticals' dependence on third parties. For a discussion of certain risks and uncertainties associated with Juniper Pharmaceuticals' forward-looking statements, please review the Company's reports filed with the SEC, including, but not limited to, its Annual Report on Form 10-K for the period ended December 31, 2016 and its subsequent filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. These statements are based on management's current expectations and Juniper Pharmaceuticals does not undertake any responsibility to revise or update any forward-looking statements contained herein, except as expressly required by law.

Investor Contact:
Argot Partners
Laura Perry or Heather Savelle
212-600-1902
laura@argotpartners.com
heather@argotpartners.com

Media Contact:
Steve Frankel / Michael Landau
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449

To receive Juniper's press releases, SEC filings or calendar alerts by email click here.
Follow us on LinkedIn

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/juniper-pharmaceuticals-announces-results-of-2017-annual-meeting-300483606.html

SOURCE Juniper Pharmaceuticals, Inc.